Current Value
$28.601 Year Return
Current Value
$28.601 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ATEC | -11.98% | $1.71B | +8.81% | 0.00% |
UNH | -9.74% | $281.72B | -37.01% | 2.65% |
PDD | -8.40% | $143.27B | -31.68% | 0.00% |
ROOT | -8.27% | $2.49B | +244.56% | 0.00% |
ALHC | -8.22% | $3.05B | +90.62% | 0.00% |
DFDV | -7.61% | $380.05M | +2,345.35% | 0.00% |
ELV | -7.16% | $86.07B | -28.21% | 1.74% |
MOH | -6.55% | $15.97B | -3.35% | 0.00% |
CNC | -6.48% | $27.50B | -18.37% | 0.00% |
UUU | -6.27% | $7.36M | +96.30% | 0.00% |
XGN | -5.41% | $158.67M | +268.53% | 0.00% |
PSN | -5.34% | $7.44B | -9.42% | 0.00% |
PPC | -4.76% | $10.70B | +45.42% | 0.00% |
K | -4.73% | $28.31B | +38.89% | 2.82% |
ICFI | -4.72% | $1.59B | -39.83% | 0.64% |
VHC | -4.64% | $37.77M | +135.71% | 0.00% |
AQB | -4.64% | $3.52M | -50.00% | 0.00% |
BTCT | -4.44% | $21.81M | +56.22% | 0.00% |
FVRR | -4.12% | $1.14B | +28.22% | 0.00% |
CEG | -3.72% | $91.58B | +33.95% | 0.49% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
BEAM | 35.81% | $1.80B | -31.35% | 0.00% |
RGNX | 35.25% | $511.64M | -22.43% | 0.00% |
CMPS | 35.02% | $426.17M | -32.89% | 0.00% |
NTLA | 34.31% | $866.99M | -67.62% | 0.00% |
CRSP | 33.97% | $3.59B | -35.96% | 0.00% |
MCY | 33.63% | $3.60B | +23.81% | 1.96% |
RY | 33.20% | $180.35B | +21.21% | 3.24% |
DNLI | 32.46% | $2.21B | -29.48% | 0.00% |
ARWR | 32.44% | $2.31B | -35.04% | 0.00% |
BNT | 32.34% | $11.90B | +41.42% | 0.00% |
BN | 32.18% | $97.47B | +41.16% | 0.56% |
ARW | 32.15% | $6.45B | -6.79% | 0.00% |
APTV | 32.10% | $15.28B | -6.75% | 0.00% |
OEC | 31.86% | $671.30M | -50.17% | 0.91% |
MOV | 31.48% | $355.57M | -35.78% | 9.01% |
BUD | 31.18% | $124.77B | +15.76% | 1.58% |
ABCL | 31.05% | $964.11M | -5.56% | 0.00% |
ALLO | 30.98% | $317.16M | -43.58% | 0.00% |
PRU | 30.86% | $37.03B | -9.00% | 5.09% |
GMAB | 30.54% | $13.91B | -15.47% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
TK | -0.02% | $700.24M | +3.86% | 0.00% |
RELY | 0.04% | $4.09B | +53.25% | 0.00% |
AMT | -0.04% | $100.35B | +10.60% | 3.04% |
ANGO | -0.07% | $442.62M | +77.52% | 0.00% |
CHE | -0.10% | $8.03B | +1.40% | 0.36% |
GRND | 0.14% | $4.56B | +155.60% | 0.00% |
VSA | -0.17% | $8.67M | -17.07% | 0.00% |
PARAA | -0.18% | $15.25B | +17.32% | 0.89% |
MKTX | 0.23% | $8.44B | +11.89% | 1.32% |
SXC | -0.33% | $704.30M | -13.51% | 5.83% |
MNOV | -0.37% | $66.70M | +0.74% | 0.00% |
NEUE | 0.37% | $60.80M | +26.11% | 0.00% |
COR | -0.38% | $55.56B | +24.55% | 0.74% |
LNG | -0.38% | $52.12B | +48.30% | 0.83% |
STG | -0.40% | $32.24M | -0.16% | 0.00% |
RRGB | -0.42% | $103.22M | -28.85% | 0.00% |
CATO | -0.44% | $63.95M | -43.55% | 5.18% |
PGNY | 0.45% | $1.86B | -21.75% | 0.00% |
SAIA | -0.48% | $6.80B | -44.77% | 0.00% |
ERIE | -0.49% | $16.61B | +0.96% | 1.48% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -27.05% | $153.01M | 0.85% |
TAIL | -25.10% | $107.77M | 0.59% |
BTAL | -21.47% | $298.87M | 1.43% |
TBLL | -19.20% | $2.26B | 0.08% |
XONE | -16.46% | $634.70M | 0.03% |
GBIL | -13.44% | $6.05B | 0.12% |
UTWO | -11.17% | $374.41M | 0.15% |
SCHO | -10.79% | $10.93B | 0.03% |
VGSH | -10.22% | $22.40B | 0.03% |
USDU | -9.79% | $165.88M | 0.5% |
CLIP | -9.74% | $1.50B | 0.07% |
IBTG | -9.55% | $1.94B | 0.07% |
SHY | -9.45% | $23.88B | 0.15% |
SPTS | -9.37% | $5.78B | 0.03% |
SHV | -9.23% | $20.36B | 0.15% |
UUP | -9.06% | $209.44M | 0.77% |
IBTF | -8.99% | $2.07B | 0.07% |
BILS | -8.89% | $3.93B | 0.1356% |
BAB | -8.59% | $918.78M | 0.28% |
BILZ | -7.97% | $839.99M | 0.14% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BND | <0.01% | $127.85B | 0.03% |
AGG | -0.01% | $125.44B | 0.03% |
UGA | 0.02% | $72.57M | 0.97% |
ICSH | -0.09% | $6.15B | 0.08% |
BIV | -0.12% | $22.59B | 0.03% |
BKAG | -0.12% | $1.90B | 0% |
BBAG | -0.14% | $1.29B | 0.03% |
FLCB | 0.22% | $2.55B | 0.15% |
XHLF | -0.24% | $1.64B | 0.03% |
NYF | 0.29% | $885.04M | 0.25% |
FLMI | 0.30% | $694.47M | 0.3% |
SHYM | 0.31% | $324.05M | 0.35% |
CGMU | 0.33% | $3.27B | 0.27% |
BLV | -0.36% | $5.61B | 0.03% |
BSMR | 0.37% | $255.06M | 0.18% |
GSY | -0.38% | $2.76B | 0.22% |
SCMB | 0.39% | $1.98B | 0.03% |
MUST | -0.39% | $429.62M | 0.23% |
IBDR | -0.43% | $3.30B | 0.1% |
CGSM | -0.44% | $683.80M | 0.25% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
GNOM | 38.28% | $44.34M | 0.5% |
ARKG | 34.48% | $980.60M | 0.75% |
IDHQ | 34.34% | $461.42M | 0.29% |
PID | 34.05% | $859.11M | 0.53% |
VIGI | 33.90% | $8.34B | 0.1% |
DFE | 33.89% | $174.33M | 0.58% |
FNDC | 33.79% | $2.87B | 0.39% |
IEV | 33.63% | $2.27B | 0.61% |
IWC | 33.62% | $813.58M | 0.6% |
SPDW | 33.49% | $26.99B | 0.03% |
SPEU | 33.48% | $735.37M | 0.07% |
SCHC | 33.42% | $4.42B | 0.11% |
FICS | 33.41% | $220.97M | 0.7% |
DFAI | 33.39% | $10.27B | 0.18% |
EWL | 33.35% | $1.33B | 0.5% |
VSS | 33.25% | $9.04B | 0.07% |
IEUR | 33.23% | $6.80B | 0.09% |
VEA | 33.23% | $160.35B | 0.03% |
DFIC | 33.22% | $9.42B | 0.23% |
QAI | 33.11% | $696.67M | 0.91% |
Yahoo
Data reported from the ongoing ATALANTA-1 Phase 1/2 study in a heavily pretreated relapsed refractory non-Hodgkin’s Lymphoma (R/R NHL) patient population demonstrate low rates of high-grade toxicities Of the 64 patients enrolled, 61 received treatment, resulting in a 5% attrition rate, significantly lower than industry benchmarks. 95% of patients were infused with fresh, stem-like early memory CD19 CAR-T cells, with 89% receiving treatment within 7 days, avoiding the need for cryopreservation an
Yahoo
Mechelen, Belgium; May 27, 2025, 22:30 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 925,000 subscription rights under a new subscription right plan. On May 27, 2025, the Board of Directors of Galapagos approved “Subscription Right Plan 2025 (A)”, intended for personnel of the Company, within the framework of the authorized capital. Under this subscription right plan, 925,000 subscription rights were created, subject to ac
Yahoo
Mechelen, Belgium; May 14, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced that new data from our ongoing ATALANTA-1 Phase 1/2 study of GLPG5101 in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) have been accepted for oral presentations at the 2025 European Hematology Association (EHA) Congress taking place June 12-15, 2025, in Milan, Italy, and the
Yahoo
Galapagos to re-evaluate the implementation of the previously announced separation following regulatory and market developments Galapagos to explore all strategic alternatives for its existing businesses, including cell therapy, with a focus on maximizing resources available for transformative business development transactions Mr. Henry Gosebruch appointed by the Galapagos Board of Directors as CEO of Galapagos, effective immediately, succeeding Dr. Paul Stoffels who announced his retirement in
Yahoo
Galapagos ( AMS:GLPG ) First Quarter 2025 Results Key Financial Results Revenue: €75.0m (up 20% from 1Q 2024). Net...
SeekingAlpha
Galapagos reported promising results from ATALANTA-1 study show 100% ORR/CR for relapsed Mantle Cell Lymphoma. Click for GLPG stock prospects post Q1 earnings.